Compare
Cellectar Biosciences, Inc. vs Aprea Therapeutics, Inc. vs Exicure, Inc. vs CytoDyn Inc.
| Latest fiscal year | Cellectar Biosciences, Inc. CLRB | Aprea Therapeutics, Inc. APRE | Exicure, Inc. XCUR | CytoDyn Inc. CYDY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-05-31 |
| Revenue | n/a | n/a | $0 | n/a |
| Revenue growth (YoY) | n/a | n/a | -100.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$21.79M | -$12.60M | -$4.95M | -$42.70M |
| EPS (Diluted) | -$8.35 | -$1.93 | -$0.79 | -$0.03 |
| Operating cash flow | -$23.12M | -$12.89M | -$8.55M | -$17.25M |
| Free cash flow | -$23.12M | n/a | -$8.56M | n/a |
| Cash & equivalents | $13.20M | $14.60M | n/a | $11.85M |
| Total assets | $14.98M | $15.93M | $14.04M | $13.97M |
| Total liabilities | $5.06M | n/a | $10.12M | $123.69M |
| Shareholders' equity | $8.54M | $12.44M | $3.93M | -$109.72M |
| Return on year-end equity | -255.2% | -101.3% | -126.0% | n/a |
| Shares outstanding | 4.24M | 8.19M | 6.37M | 1.37B |
Revenue, most recent five fiscal years
| Fiscal year | Cellectar Biosciences, Inc. | Aprea Therapeutics, Inc. | Exicure, Inc. | CytoDyn Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $0 Ended 2025-12-31 | $0 Ended 2023-05-31 |
| 1 year earlier | n/a | n/a | $500.0K Ended 2024-12-31 | $266.0K Ended 2022-05-31 |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | $0 Ended 2021-05-31 |
| 3 years earlier | n/a | n/a | $28.83M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | -$483.0K Ended 2021-12-31 | n/a |